视黄酸受体反应蛋白1在肾细胞癌中的表达及其与临床病理特征的相关性
Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas.
作者信息
Zimpfer Annette, Dammert Friedericke, Glass Aenne, Zettl Heike, Kilic Ergin, Maruschke Matthias, Hakenberg Oliver W, Erbersdobler Andreas
机构信息
Institute of Pathology, University Medicine Rostock, Strempelstr. 14, 18055 Rostock, Germany.
Institute of Pathology, University Hospital of Jena, Ziegelmühlenweg 1, 07743 Jena, Germany.
出版信息
Biomark Med. 2016 Jul;10(7):721-32. doi: 10.2217/bmm.16.12. Epub 2016 Jun 24.
AIM
To evaluate the expression and prognostic value of RARRES1 at protein level in renal cell carcinoma (RCC).
MATERIALS & METHODS: Expression profile of RARRES1 was analyzed in 903 documented RCC followed by clinicopathological correlations and survival analysis.
RESULTS
RARRES1 expression was seen in 72.5% of RCC. A stronger RARRES1 expression was seen in high grade compared with low grade RCC (p < 0.001). Logrank tests revealed shorter overall survival in RARRES1 positive RCC (p = 0.006) and in pT1/2 tumors with RARRES1 expression (p = 0.002).
CONCLUSION
The variable expression profile in low and high grade RCC may reflect and confirm the differences of previous gene expression analysis. There was a significant prognostic value of RARRES1 expression in patients with RCC, especially in pT1/2 tumors.
目的
评估视黄酸受体应答蛋白1（RARRES1）在肾细胞癌（RCC）中蛋白水平的表达及预后价值。
材料与方法
分析903例有记录的肾细胞癌中RARRES1的表达谱，随后进行临床病理相关性分析和生存分析。
结果
72.5%的肾细胞癌中可见RARRES1表达。与低级别肾细胞癌相比，高级别肾细胞癌中RARRES1表达更强（p < 0.001）。对数秩检验显示，RARRES1阳性的肾细胞癌总生存期较短（p = 0.006），RARRES1表达的pT1/2肿瘤总生存期也较短（p = 0.002）。
结论
低级别和高级别肾细胞癌中RARRES1的可变表达谱可能反映并证实了先前基因表达分析的差异。RARRES1表达在肾细胞癌患者中具有显著的预后价值，尤其是在pT1/2肿瘤中。
Zotero 插件